低级别胶质瘤患者接受同期替莫唑胺放化疗或观察后的生活质量
该回顾性横断面研究纳入1980至2018年接受手术且分子分型明确的63例低级别胶质瘤成人患者,术后观察30例(48%)或接受同期替莫唑胺放化疗33例(52%)。所有患者术后3、6、9、12及24个月EQ-5D或PHQ-9评分较基线无显著下降,两治疗组间及各时间点间亦无显著差异。
要点
- 低级别胶质瘤术后2年内患者报告的生活质量与抑郁评分无显著下降。
- 同期替莫唑胺放化疗组与观察组在EQ-5D及PHQ-9评分上无显著差异。
- 线性混合模型显示组间与时间点均无显著差异(EQ-5D组间p=0.54,PHQ-9组间p=0.42)。
核心结论
- 低级别胶质瘤患者术后2年内患者报告结局评估的生活质量或抑郁评分无显著下降,同期替莫唑胺放化疗与观察之间无差异。
研究设计与样本
- 回顾性横断面研究,纳入1980至2018年接受手术且分子分型明确的低级别胶质瘤成人患者63例,平均年龄44±17岁,女性占51%。
主要发现
- 63例中观察组30例(48%),接受同期替莫唑胺放化疗组33例(52%)。
- 所有患者术后3、6、9、12及24个月EQ-5D或PHQ-9评分较基线无显著下降。
- 各时间点观察组与辅助治疗组之间无显著差异。
- 线性混合模型显示PHQ-9组间p=0.42、EQ-5D指数组间p=0.54,时间点间p=0.24和p=0.99,均无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Low-grade glioma (LGG) exhibits longer median survival than high-grade brain tumors, and thus impact of our therapies on patient quality of life remains a crucial consideration. This study evaluated the effects of concurrent temozolomide-based chemoradiation (RT + TMZ) or observation on quality of life (QOL) in patients with low-grade glioma. METHODS: We completed a retrospective cross-sectional study of adults with LGG who underwent surgery with known molecular classification from 1980 to 2018. Postoperatively, patients were either observed or received adjuvant concurrent temozolomide-based chemoradiation. EQ-5D and PHQ-9 depression screen were completed before outpatient visits every 2-3 months. Baseline score was defined as ± 30 days within initial operation. RESULTS: Of the 63 patients (mean age 44 ± 17 years, 51% female) with baseline EQ-5D or PHQ-9 depression screen data and at least one follow-up measure, 30 (48%) were observed and 33 (52%) received RT + TMZ. No significant decline was seen in EQ-5D or PHQ-9 scores at 3, 6, 9, 12, and 24 months compared to baseline scores for all patients. At each time point, there was no significant difference between those who were observed or received adjuvant therapy. The linear mixed model estimating PHQ-9 value or EQ-5D index demonstrated that there was no significant difference in PHQ-9 or EQ-5D index between treatment groups (p = 0.42 and p = 0.54, respectively) or time points (p = 0.24 and p = 0.99, respectively). CONCLUSION: Our study found no significant decline in patient QOL or depression scores as assessed by patient- reported outcome measures for patients with low-grade glioma up to 2 years following surgery. We found no difference between RT + TMZ compared to observation during this time frame. Additional follow-up can help identify the longer-term impact of treatment strategy on patient experience.
引用
- Park DY, Tom MC, Wei W, et al. Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma. J Neurooncol. 2022. PMID: 35064450. doi:10.1007/s11060-021-03920-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。